On November 6, 2025, the Trump administration announced new pricing and coverage agreements with Eli Lilly and Novo Nordisk for widely used glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide (Mounjaro®, Zepbound®) and semaglutide (Ozempic®, Wegovy®). These agreements aim to lower out-of-pocket costs for some patients and expand access under federal health programs beginning in 2026. […]
Tag Archives: Healthcare Challenges
AI-enabled Care, ATLMed News, Healthcare Challenges
Bringing AI-Enabled Care to Rural America: From Bandwidth to Bedside
10
Dec
Dec
Rural communities across the United States continue to face deep, long-standing healthcare challenges: long travel distances to clinics, shortages of specialists, hospital closures, and limited access to timely, high-quality care. These barriers contribute to higher rates of chronic disease, later diagnoses, and poorer health outcomes for millions of rural residents. A recent perspective in the […]